|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that VEGF blockade coupled with glioma-derived glutamate induces systemic and intratumoral immunosuppression by promoting Treg overrepresentation and function, which can be pre-emptively overcome through Treg depletion for enhanced antitumor effects.
|
31723000 |
2020 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe 3 key mechanisms related to vascular endothelial growth factor (VEGF)-mediated immunosuppression: inhibition of dendritic cell maturation, reduction of T-cell tumor infiltration, and promotion of inhibitory cells in the tumor microenvironment; supporting data are also described.
|
30119083 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results propose a rationale to overcome tumor immunosuppression and the current limitations of VEGF monotherapy by integrating the synergistic effects of VEGF/Ang-2 and PD-1 blockade to reinforce antitumor immunity through a normalized vasculature.
|
31597643 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gradually increasing amounts of ascites were correlated significantly, even after correction for FIGO stage, with reduced survival (p<0.0001) and stronger immunosuppression (IL10 and VEGF).
|
31704820 |
2019 |
|
Immunosuppression
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given that vascular endothelial growth factor (VEGF) and placental growth factor (PIGF), over-expressed in breast cancer cells and M2-like tumor-associated macrophages (M2-TAMs) within tumor microenvironment (TME), work synergistically and independently in mediating tumor progression and immunosuppression, combinatorial immune-based approaches targeting them are expected to be a potent therapeutic modality for patients.
|
30241030 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF plays a key role in tumor angiogenesis and immunosuppression.
|
30259696 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several studies have established a correlation between the VEGF-VEGFR2 axis and an immunosuppressive microenvironment; this immunosuppression can be overcome by anti-angiogenic reagents, such as ramucirumab (RAM).
|
30314524 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab.
|
29863955 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA sequencing revealed further genetic differences between these two cell populations and MSC-like cells lacking CD90 produced higher amounts of VEGF and PGE<sub>2</sub> compared to cells with the true MSC phenotype, implying that the CD90<sup>-</sup> MSC-like cells most probably are more active in tumor vascularization and immunosuppression than their CD90<sup>+</sup> counterpart.
|
27757723 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
To overcome tumor-mediated immunosuppression and enhance the potency of immunogene therapy, oncolytic adenovirus (Ad) co-expressing interleukin (IL)-12 and vascular endothelial growth factor (VEGF)-specific short hairpin ribonucleic acid (shVEGF; RdB/IL12/shVEGF) was generated.
|
27821803 |
2016 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
STAT3-dependent VEGF production from keratinocytes abrogates dendritic cell activation and migration by arsenic: a plausible regional mechanism of immunosuppression in arsenical cancers.
|
25559853 |
2015 |
|
Immunosuppression
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Briefly, female Wistar rats--under cyclosporin immunosuppression--received a 35 g clip-compression injury and were administered AdV-ZFP-VEGF or AdV-eGFP at 24 hours post-SCI. qRT-PCR and Western Blot analysis of VEGF-A mRNA and protein, showed significant increases in VEGF-A expression in AdV-ZFP-VEGF treated animals (p<0.001 and p<0.05, respectively).
|
24846143 |
2014 |
|
Immunosuppression
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Once epidermal genetic mutations and aberrant molecular signaling have occurred, the stroma responds through a 3-phase process-extracellular matrix degradation is produced by matrix metalloproteinases; angiogenesis is induced by vascular endothelial growth factor and mast cell mediators; and the inflammatory response is elicited by cytokines and cyclin D1 overexpression balanced by the immunosuppression of mast cell mediators such as tumor necrosis factor alpha, histamine, and transforming growth factor beta.
|
21785326 |
2011 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF), which was originally discovered as vascular permeability factor, is critical to human cancer angiogenesis through its potent functions as a stimulator of endothelial cell survival, mitogenesis, migration, differentiation and self-assembly, as well as vascular permeability, immunosuppression and mobilization of endothelial progenitor cells from the bone marrow into the peripheral circulation.
|
15450248 |
2004 |